Nuvation Bio Inc.

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative cancer therapies. The company's strategic focus lies in identifying and advancing novel drug candidates with the potential to address significant unmet medical needs in oncology. Its most advanced program, taletrectinib, is an investigational ROS1 inhibitor designed for patients with ROS1-positive non-small cell lung cancer, a targeted therapy approach that aims to improve patient outcomes. Beyond this lead candidate, Nuvation Bio is advancing a diversified pipeline including safusidenib, an inhibitor targeting mutant isocitrate dehydrogenase 1, which is currently in Phase 2 clinical trials. The company is also exploring NUV-1511, a novel drug-drug conjugate intended to combat a range of advanced solid tumors by delivering potent chemotherapy agents directly to cancer cells. Furthermore, NUV-868, a bromodomain and extra-terminal (BET) inhibitor, is under development to target the bromodomain-containing protein 4, a mechanism implicated in various cancers. Nuvation Bio's business model centers on rigorous scientific research, efficient clinical development, and strategic partnerships to bring these promising oncology treatments to patients.